Valneva SE announced this week that the first participant has been vaccinated in the Phase 2 clinical trial evaluating the safety and Immunogenicity in children of two different dose levels of Valneva’s...

NewsDesk @bactiman63 Cocrystal Pharma announced the of the first subjects in a Phase 1 clinical trial with its oral, first-in-class pan-norovirus and pan-coronavirus 3CL protease inhibitor CDI-988.  This...

NewsDesk @bactiman63 An antibiotic that has shown effectiveness for bacterial pneumonia also appears successful in fighting methicillin-resistant staph infections, reports a team led by Duke Health. The...

NewsDesk @bactiman63 The U.S. Food and Drug Administration (FDA) has approved Sanofi and AstraZeneca’s Beyfortus™ (nirsevimab-alip) for the prevention of respiratory syncytial virus (RSV) lower respiratory...

NewsDesk @bactiman63 Last week, the U.S. Food and Drug Administration approved Xacduro (sulbactam for injection; durlobactam for injection), a new treatment for hospital-acquired bacterial pneumonia...

NewsDesk @bactiman63 Last week, the U.S. Food and Drug Administration approved the oral antiviral Paxlovid (nirmatrelvir tablets and ritonavir tablets, co-packaged for oral use) for the treatment of mild-to-moderate...

NewsDesk @bactiman63 Nirsevimab is a long-acting antibody designed for all infants for protection against RSV disease from birth through their first RSV season with a single dose, is being developed jointly...

NewsDesk @bactiman63 Mpox patients treated with tecovirimat, an antiviral drug widely used since last summer’s outbreak, had similar outcomes regardless of HIV status, researchers at Columbia University’s...

NewsDesk @bactiman63 On Monday, the CDC reported an increasing threat of the emerging fungus Candida auris. Today, the U.S. FDA today approved Cidara Therapeutics and Melinta Therapeutics’ REZZAYOTM...

NewsDesk @bactiman63 Researchers from the Antimicrobial Resistance (AMR) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT’s research enterprise...